
FDA Approves Drug to Identify Ovarian Cancer Lesions During Surgery
In what could prove to be a game-changer for ovarian cancer debulking procedures, the U.S. Food and Drug Administration (FDA) has approved Cytalux (pafolacianine), an imaging drug designed to help doctors better locate and identify ovarian cancer lesions during surgery. The drug, which is administered via injection at the time of surgery, works by binding … Continued